Expanded IP covers Tet transactivators and is available under license.

TET Systems acquired rights to eight patent applications covering new Tet transactivators from The Netherlands-based Academic Medical Center (AMC) and  Technology Foundation STW. The company says that the patent assignment will broaden its IP portfolio.

TET Systems’ technology is used to effect precise and reversible control over both the timing and level of gene expression in eukaryotic cells. The technology is, according to the company, the most widely applied inducible gene-expression system.

“Since TET Systems was established in 2004, all relevant IP covering the Tet Technology was in one hand and could be offered to our licensees as a package,” explains CEO, Ernst Boehnlein Ph.D. “With the acquisition of these patent applications from AMC and STW, we broadened our IP portfolio and the rights to the core Tet Technology are again unified. From now on, interested parties can again do one-stop shopping for the relevant Tet Technology.”

Previous articleStanching the Action of Anticoagulants
Next articleAstraZeneca Provides $200M Up Front to Develop Targacept’s Late-Stage Candidate for Depression